Glycotope Presents Phase I Results of Novel Glycooptimized Monoclonal anti-TA-MUC1 Antibody PankoMab-GEXTM at European Cancer Congress

Glycotope GmbH, a global leader in optimising the glycosylation of biopharmaceuticals and carbohydrate-specific antibodies (GlycoBodies), is presenting first-in-human results of their Phase I study of PankoMab-GEX, a glycoengineered antibody against their novel TA-MUC1 epitope, which is tumour-specific and abundantly present on many solid cancers, at this year's European Cancer Congress (ECCO 17). The annual congress is taking place from 27 September to 1 October in Amsterdam. Glycotope participated with a poster presentation in the session "Drug Development" on Sunday 29 September 2013.

Eligible patients with TA-MUC1 positive advanced solid tumours, progressing after standard treatments, were enrolled into this Phase I trial. Primary endpoints were safety and tolerability. Pharmacokinetics, immunogenicity and anti-tumour activity were also assessed.

PankoMab-GEXTM clearly demonstrated clinical activity as single agent in heavily pre-treated patients with far advanced cancers and could be safely administered at all tested doses and schedules with a very favorable safety, side effect and pharmacokinetic profile.